Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Acetanilide is a small molecule organic compound that was historically the first aniline derivative used as an analgesic and antipyretic under the brand name Antifebrin. Although its systemic use has been largely superseded by its metabolite, paracetamol (acetaminophen), due to the risk of methemoglobinemia, it remains relevant in specific therapeutic contexts. Notably, it is developed and utilized by the Gansu Provincial Hospital of TCM as a topical treatment for osteofascial compartment syndrome (OCS). In this application, acetanilide is believed to alleviate local pain and inflammation, improve microcirculation, and reduce tissue pressure, thereby helping to prevent the severe ischemic complications associated with OCS. Its primary mechanism involves the inhibition of cyclooxygenase (COX) enzymes, which reduces the production of pro-inflammatory prostaglandins.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on acetanilide.